FAQ: Oncotelic Therapeutics' Sapu Nano Venture Begins Clinical Trials for Innovative Breast Cancer Therapy
TL;DR
Oncotelic's Sapu Nano secured HREC approval for Sapu003 trials, potentially achieving superior tumor shrinkage over oral formulations and gaining a competitive edge in breast cancer treatment.
Sapu003 uses Sapu Nano's proprietary Deciparticle technology to deliver Everolimus intravenously, enabling full drug absorption directly into the bloodstream for breast cancer treatment.
This clinical trial approval represents progress toward better outcomes and improved quality of life for breast cancer patients through more effective treatment options.
Oncotelic's Sapu003 clinical trial approval marks a landmark moment in breast cancer treatment using innovative intravenous delivery technology for enhanced drug absorption.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics' venture Sapu Nano has received approval from Australia's Human Research Ethics Committee to begin enrolling patients in clinical trials for Sapu003, an injectable form of Afinitor (everolimus) for breast cancer treatment.
This approval represents a landmark moment because Sapu003's intravenous delivery system enables full drug absorption, potentially achieving meaningful tumor shrinkage where oral formulations have been limited, offering breast cancer patients better outcomes and improved quality of life.
Sapu003 uses Sapu Nano's proprietary Deciparticle technology to deliver Everolimus directly into the bloodstream through intravenous injection, enabling full drug absorption compared to oral formulations.
The program involves Oncotelic Therapeutics Inc. (OTCQB: OTLC) and its venture Sapu Nano, with support from Dr. Sud Agarwal, CEO of Ingenu (a contract research organization in Australia), and is led by Oncotelic's CEO Dr. Vuong Trieu, who has extensive patent experience.
The clinical trials are being conducted in Australia, with approval granted by Australia's Human Research Ethics Committee (HREC).
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
Beyond its internal programs, Oncotelic licenses and codevelops drug candidates through joint ventures, including owning 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic's strategic position.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
Sapu003 has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited by enabling full drug absorption through intravenous delivery, potentially giving breast cancer patients better outcomes.
Sapu003 utilizes Sapu Nano's proprietary Deciparticle technology, which enables the intravenous delivery of Everolimus directly into the bloodstream for improved drug absorption.
Curated from InvestorBrandNetwork (IBN)
